Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
Michiels JJ, van Vliet HH, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van der Velden A, Budde U. Michiels JJ, et al. Among authors: van der velden a, van vliet hh, van der planken m. Clin Appl Thromb Hemost. 2007 Jan;13(1):14-34. doi: 10.1177/1076029606296399. Clin Appl Thromb Hemost. 2007. PMID: 17164493 Free article. Review.
Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
Michiels JJ, van de Velde A, van Vliet HH, van der Planken M, Schroyens W, Berneman Z. Michiels JJ, et al. Among authors: van de velde a, van vliet hh, van der planken m. Semin Thromb Hemost. 2002 Apr;28(2):111-32. doi: 10.1055/s-2002-27814. Semin Thromb Hemost. 2002. PMID: 11992235 Clinical Trial.
Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).
Michiels JJ, Berneman ZN, van der Planken M, Schroyens W, Budde U, van Vliet HH. Michiels JJ, et al. Among authors: van vliet hh, van der planken m. Blood Coagul Fibrinolysis. 2004 Jun;15(4):323-30. doi: 10.1097/00001721-200406000-00006. Blood Coagul Fibrinolysis. 2004. PMID: 15166918 Clinical Trial.
Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.
Michiels JJ, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van de Velde A, van Vliet H. Michiels JJ, et al. Among authors: van vliet h, van de velde a, van der planken m. Clin Appl Thromb Hemost. 2006 Jul;12(3):277-95. doi: 10.1177/1076029606291401. Clin Appl Thromb Hemost. 2006. PMID: 16959681 Free article. Review.
Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
Michiels JJ, Gadisseur A, van der Planken M, Schroyens W, van de Velden A, Berneman Z. Michiels JJ, et al. Among authors: van de velden a, van der planken m. Semin Thromb Hemost. 2006 Sep;32(6):636-45. doi: 10.1055/s-2006-949669. Semin Thromb Hemost. 2006. PMID: 16977574 Review.
Classification and characterization of hereditary types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (unclassifiable) von Willebrand disease.
Michiels JJ, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van de Velde A, van Vliet H. Michiels JJ, et al. Among authors: van vliet h, van de velde a, van der planken m. Clin Appl Thromb Hemost. 2006 Oct;12(4):397-420. doi: 10.1177/1076029606293422. Clin Appl Thromb Hemost. 2006. PMID: 17000885 Free article. Review.
66 results